Results 201 to 210 of about 92,747 (232)

Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine

Drug Testing and Analysis, EarlyView.
This study investigated tesofensine metabolism and urinary elimination after a single 483 μg intake via a dietary supplement. In six volunteers, urine was collected up to 659 h. LC‐HRMS/MS identified four tentative metabolites; maximum urinary concentrations reached 4 ng/mL within 4–48 h.
O. Krug, A. Thomas, M. Thevis
wiley   +1 more source

Associations Between Microbial Depletion and Autonomic Dysregulation in Binge‐Eating Disorder

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective The interplay between the gut microbiome and autonomic nervous system remains unexplored in binge‐eating disorder (BED). We aimed to explore specific microbial alterations in BED and examine their potential association with cardiac vagal tone as a distinct bio‐behavioral phenotype.
Shuang Liang, Esben Strodl, Leanne Barron, Matthew Bambling, Luis Vitetta   +4 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Open-Label Placebo Treatment for Experimental Pain: A Randomized-Controlled Trial with Placebo Acupuncture and Placebo Pills

Journal of Integrative and Complementary Medicine, 2022
Objective: An open-label placebo (OLP) is a placebo treatment in which the patient is aware that the treatment is a placebo. OLPs are considered effective for reducing pain, and previous studies have shown a stronger placebo effect for placebo acupuncture than for placebo pills.
Seoyoung Lee, In-Seon Lee, Younbyoung Chae   +2 more
exaly   +3 more sources

A Fictionalist Account of Open-Label Placebo

Journal of Medicine and Philosophy
Abstract The placebo effect is now generally defined widely as an individual’s response to the psychosocial context of a clinical treatment, as distinct from the treatment’s characteristic physiological effects. Some researchers, however, argue that such a wide definition leads to confusion and misleading implications.
Doug Hardman
exaly   +3 more sources

Choice over placebo administration enhances open-label placebo hypoalgesia

Pain, 2023
Abstract Many studies indicate that deceptively administered placebos can improve pain outcomes. However, the deception involved presents an ethical barrier to translation because it violates informed consent and patient autonomy. Open-label placebos (OLPs), inert treatments that are openly administered as placebos, have been proposed as an ...
Biya Tang, Evan Livesey, Ben Colagiuri
openaire   +2 more sources

Open-Label Placebo: Reflections on a Research Agenda

Perspectives in Biology and Medicine, 2018
Open-label placebos (OLP)-placebo pills honestly prescribed-have challenged the notion that placebos require either deception or concealment to evoke salubrious benefits. This essay describes how the author arrived at the counter-intuitive OLP hypothesis, discusses evidence for OLP effectiveness, and examines mechanistic explanations for OLP.
openaire   +2 more sources

Deceptive but not open label placebos attenuate motion-induced nausea

Journal of Psychosomatic Research, 2019
Nausea is a common complaint, known to respond to the placebo effect. Existing research has employed deception when administering placebos for nausea, limiting therapeutic translation on ethical grounds. We therefore examined the potential of non-deceptive open-label placebos (OLPs) to reduce nausea.Galvanic Vestibular Stimulation (GVS) and Virtual ...
K, Barnes, A, Yu, J, Josupeit, B, Colagiuri   +3 more
openaire   +2 more sources